Shares of Checkpoint Therapeutics Inc (NASDAQ:CKPT) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price target of $15.50 for the company and are expecting that the company will post ($0.27) EPS for the current quarter, according to Zacks. Zacks has also assigned Checkpoint Therapeutics an industry rank of 193 out of 265 based on the ratings given to related companies.
A number of analysts have recently commented on the company. Zacks Investment Research cut Checkpoint Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. HC Wainwright assumed coverage on Checkpoint Therapeutics in a research report on Friday, December 8th. They issued a “buy” rating and a $11.00 price objective for the company.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.